Economic impact of psoriasis treatment on the patient and on the National Health Service

Autor:	P. I. Adnitt, T. F. Poyner, A. P. Menday, A. R. J. Wall
Rok vydání:	1999
Předmět:	Plaque psoriasis medicine.medical_specialty business.industry Public health Dermatology medicine.disease National health service Surgery chemistry.chemical_compound chemistry Internal medicine Psoriasis Dithranol Medicine Resource use business Psoriasis treatment Calcipotriol medicine.drug
Zdroj:	Journal of Dermatological Treatment. 10:25-29
ISSN:	1471-1753 0954-6634
DOI:	10.3109/09546639909055907
Popis:	Personal expenditure arising from psoriasis by patients with mild/moderate chronic plaque psoriasis was assessed before and at the end of randomized treatment in 122 patients treated with calcipotriol for a mean of 12 weeks and in 110 patients treated with dithranol for a mean of 11 weeks. Mean monthly expenditure before calcipotriol treatment was ±15.23 (median ±11.00) and was ±13.54 (median ±6.00) during calcipotriol treatment. Mean monthly expenditure before dithranol treatment was ±15.97 (median ±6.00) and was ±16.89 (median ±11.00) during dithranol treatment. When compared with calcipotriol treatment, dithranol treatment tended to result in increased monthly expenditure (P=0.08), primarily on purchasing new clothing (P=0.03) and new bed-linen/towels (P=0.06). Healthcare resource use by the National Health Service (NHS), in respect of general practitioner (GP) and hospital consultation and treatment, was also assessed for two separate 6-month periods, before (period I) and after (period II) randomized...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::74ba1b52cf3b24dac7d6fc0518dfcf14 https://doi.org/10.3109/09546639909055907 Zobrazit plný text záznamu Plný text ve formátu PDF